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Summary 
The U.S. Food and Drug Administration (FDA) has issued a safety communication warning about the use 
of Magellan Diagnostics’ LeadCare® analyzers (LeadCare, LeadCare II, LeadCare Ultra and LeadCare 
Plus) with venous blood samples because they might result in falsely low test results. FDA is now 
advising that Magellan Diagnostics’ LeadCare® analyzers should no longer be used with venous blood 
samples. The safety alert does not apply to capillary blood lead test results collected by fingerstick or 
heelstick. The purpose of this Health Advisory is to notify state and local health departments, healthcare 
providers, and laboratories about CDC’s re-testing guidance in light of the safety alert. 
 
Background 
CDC was contacted on April 24, 2017 by FDA requesting assistance in assessing the potential public 
health risk of a negative bias associated with Magellan’s lead testing systems. FDA is now warning that 
Magellan Diagnostics’ LeadCare® analyzers should no longer be used with venous blood samples due to 
the potential for falsely low test results. Not all blood lead tests are affected. Laboratory tests analyzed by 
inductively coupled plasma-mass spectrometry (ICP-MS) or graphite furnace atomic spectrometry 
(GFAAS) (also known as electrothermal atomic absorption spectrometry [ETAAS]) are not expected to 
have resulted in falsely low results. This safety alert applies to venous blood lead tests conducted using 
Magellan Diagnostics’ LeadCare® analyzers whether the patient is a child or an adult. At this time, the 
safety alert does not apply to capillary blood lead test results collected by fingerstick or heelstick using 
Magellan Diagnostics’ LeadCare® analyzers. Children are particularly vulnerable to lead exposure due to 
the effect on their developing brains and organ systems. CDC is working with public health officials 
throughout the United States to determine where the analyzers were used and which blood lead test 
results might be affected. 
 
Recommendations 
 
CDC recommends that healthcare providers re-test patients who: 
1) are younger than 6 years (72 months) of age at the time of the alert (May 17, 2017) and  
2) had a venous blood lead test result of less than 10 micrograms per deciliter (µg/dL) analyzed 
using a Magellan Diagnostics’ LeadCare® analyzer at an onsite (e.g., healthcare facility) or at 
an offsite laboratory. 
 
CDC also recommends that healthcare providers re-test currently pregnant or lactating women who had a 
venous blood lead test performed using a Magellan Diagnostics’ LeadCare® analyzer.  
 
CDC recommends parents discuss re-testing with their healthcare provider or health department to 
determine if their child’s blood should be re-tested.  
 
If re-testing indicates blood lead levels in excess of the CDC reference level 
(www.cdc.gov/nceh/lead/acclpp/blood_lead_levels.htm), or the state or local action level, the healthcare 
provider or public health official should refer to CDC and/or local guidelines for appropriate follow-up 
action (www.cdc.gov/nceh/lead/acclpp/actions_blls.html).  
 
Re-tests are not recommended if the provider is certain that analyzers other than those described by this 
Health Advisory were used to analyze the venous blood samples.  
 
For future blood lead testing, healthcare providers and public health officials should:  
 Send venous samples to Clinical Laboratory Improvement Amendments (CLIA)-compliant 
laboratories using inductively coupled plasma mass spectrometry (ICP-MS) or graphite furnace 
atomic absorption spectrometry (GFAAS) (also known as electrothermal atomic absorption 
spectrometry [ETAAS]) instruments.  
 Send capillary samples to CLIA-compliant laboratories using any CLIA compliant analyzer 
including ICP-MS, GFAAS, or LeadCare® analyzers. 
 
 
For More Information  
 
CDC’s Lead Poisoning Prevention Program: https://www.cdc.gov/nceh/lead/ 
 
CDC’s Lead and Multi-element Proficiency Program: https://www.cdc.gov/labstandards/lamp.html 
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FDA safety communication warning, May 17, 2017. Available at: 
https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm558733.htm 
 
 
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing 
and controlling diseases and injuries; enhances health decisions by providing credible information on 
critical health issues; and promotes healthy living through strong partnerships with local, national, and 
international organizations. 
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